nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—OPRM1—nerve—acquired immunodeficiency syndrome	0.00807	0.189	CbGeAlD
Pentazocine—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.0051	0.0278	CbGpPWpGaD
Pentazocine—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00447	0.0244	CbGpPWpGaD
Pentazocine—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00396	0.0216	CbGpPWpGaD
Pentazocine—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00378	0.0206	CbGpPWpGaD
Pentazocine—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00347	0.0189	CbGpPWpGaD
Pentazocine—EBP—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.00319	0.0174	CbGpPWpGaD
Pentazocine—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00293	0.016	CbGpPWpGaD
Pentazocine—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00285	0.0156	CbGpPWpGaD
Pentazocine—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00268	0.0146	CbGpPWpGaD
Pentazocine—OPRD1—nervous system—acquired immunodeficiency syndrome	0.00266	0.0624	CbGeAlD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00265	0.0145	CbGpPWpGaD
Pentazocine—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00256	0.0601	CbGeAlD
Pentazocine—OPRK1—nervous system—acquired immunodeficiency syndrome	0.00255	0.0599	CbGeAlD
Pentazocine—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0025	0.0136	CbGpPWpGaD
Pentazocine—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.00246	0.0576	CbGeAlD
Pentazocine—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.0024	0.0131	CbGpPWpGaD
Pentazocine—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00235	0.0128	CbGpPWpGaD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00233	0.0127	CbGpPWpGaD
Pentazocine—OPRM1—blood—acquired immunodeficiency syndrome	0.00224	0.0525	CbGeAlD
Pentazocine—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00217	0.0118	CbGpPWpGaD
Pentazocine—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.00215	0.0505	CbGeAlD
Pentazocine—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00211	0.0115	CbGpPWpGaD
Pentazocine—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.0021	0.0115	CbGpPWpGaD
Pentazocine—OPRD1—brain—acquired immunodeficiency syndrome	0.00203	0.0477	CbGeAlD
Pentazocine—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00202	0.011	CbGpPWpGaD
Pentazocine—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00198	0.0108	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00197	0.0107	CbGpPWpGaD
Pentazocine—OPRK1—brain—acquired immunodeficiency syndrome	0.00195	0.0458	CbGeAlD
Pentazocine—Loss of consciousness—Indinavir—acquired immunodeficiency syndrome	0.00193	0.00249	CcSEcCtD
Pentazocine—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.00192	0.00248	CcSEcCtD
Pentazocine—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.00192	0.00248	CcSEcCtD
Pentazocine—Erythema multiforme—Saquinavir—acquired immunodeficiency syndrome	0.00191	0.00247	CcSEcCtD
Pentazocine—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.00191	0.00247	CcSEcCtD
Pentazocine—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.0019	0.00246	CcSEcCtD
Pentazocine—Agitation—Efavirenz—acquired immunodeficiency syndrome	0.0019	0.00246	CcSEcCtD
Pentazocine—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.0019	0.0104	CbGpPWpGaD
Pentazocine—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.00189	0.00245	CcSEcCtD
Pentazocine—Constipation—Stavudine—acquired immunodeficiency syndrome	0.00189	0.00244	CcSEcCtD
Pentazocine—Shock—Zidovudine—acquired immunodeficiency syndrome	0.00189	0.00244	CcSEcCtD
Pentazocine—Tinnitus—Saquinavir—acquired immunodeficiency syndrome	0.00189	0.00244	CcSEcCtD
Pentazocine—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.00189	0.00244	CcSEcCtD
Pentazocine—Chills—Ritonavir—acquired immunodeficiency syndrome	0.00189	0.00244	CcSEcCtD
Pentazocine—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.00188	0.00242	CcSEcCtD
Pentazocine—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.00187	0.00241	CcSEcCtD
Pentazocine—Vertigo—Efavirenz—acquired immunodeficiency syndrome	0.00186	0.0024	CcSEcCtD
Pentazocine—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.00186	0.0024	CcSEcCtD
Pentazocine—Syncope—Efavirenz—acquired immunodeficiency syndrome	0.00186	0.0024	CcSEcCtD
Pentazocine—Tremor—Delavirdine—acquired immunodeficiency syndrome	0.00186	0.0024	CcSEcCtD
Pentazocine—SIGMAR1—blood—acquired immunodeficiency syndrome	0.00185	0.0433	CbGeAlD
Pentazocine—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00184	0.01	CbGpPWpGaD
Pentazocine—Anorexia—Zidovudine—acquired immunodeficiency syndrome	0.00183	0.00237	CcSEcCtD
Pentazocine—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.00183	0.00236	CcSEcCtD
Pentazocine—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00183	0.00236	CcSEcCtD
Pentazocine—Erythema multiforme—Lamivudine—acquired immunodeficiency syndrome	0.00183	0.00236	CcSEcCtD
Pentazocine—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.00182	0.00236	CcSEcCtD
Pentazocine—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.00182	0.00235	CcSEcCtD
Pentazocine—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.00182	0.00235	CcSEcCtD
Pentazocine—Chills—Saquinavir—acquired immunodeficiency syndrome	0.00182	0.00235	CcSEcCtD
Pentazocine—OPRM1—nervous system—acquired immunodeficiency syndrome	0.00182	0.0426	CbGeAlD
Pentazocine—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.0018	0.00233	CcSEcCtD
Pentazocine—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.0018	0.00232	CcSEcCtD
Pentazocine—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	0.00179	0.00232	CcSEcCtD
Pentazocine—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.00179	0.00231	CcSEcCtD
Pentazocine—SIGMAR1—bone marrow—acquired immunodeficiency syndrome	0.00179	0.0419	CbGeAlD
Pentazocine—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.00179	0.00231	CcSEcCtD
Pentazocine—SIGMAR1—spinal cord—acquired immunodeficiency syndrome	0.00178	0.0418	CbGeAlD
Pentazocine—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.00178	0.0023	CcSEcCtD
Pentazocine—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00178	0.00229	CcSEcCtD
Pentazocine—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00178	0.0097	CbGpPWpGaD
Pentazocine—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.00178	0.00229	CcSEcCtD
Pentazocine—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00177	0.00968	CbGpPWpGaD
Pentazocine—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.00176	0.00227	CcSEcCtD
Pentazocine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00176	0.00227	CcSEcCtD
Pentazocine—Shock—Indinavir—acquired immunodeficiency syndrome	0.00176	0.00227	CcSEcCtD
Pentazocine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00175	0.00226	CcSEcCtD
Pentazocine—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.00175	0.041	CbGeAlD
Pentazocine—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00174	0.00225	CcSEcCtD
Pentazocine—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.00174	0.00225	CcSEcCtD
Pentazocine—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.00174	0.00225	CcSEcCtD
Pentazocine—Chills—Lamivudine—acquired immunodeficiency syndrome	0.00173	0.00224	CcSEcCtD
Pentazocine—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.00173	0.00946	CbGpPWpGaD
Pentazocine—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.00173	0.00946	CbGpPWpGaD
Pentazocine—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.00173	0.00223	CcSEcCtD
Pentazocine—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.00173	0.00223	CcSEcCtD
Pentazocine—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.00173	0.00223	CcSEcCtD
Pentazocine—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00173	0.00223	CcSEcCtD
Pentazocine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.00172	0.00223	CcSEcCtD
Pentazocine—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.00172	0.00222	CcSEcCtD
Pentazocine—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.00171	0.00221	CcSEcCtD
Pentazocine—SIGMAR1—vagina—acquired immunodeficiency syndrome	0.00171	0.0402	CbGeAlD
Pentazocine—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.00171	0.00221	CcSEcCtD
Pentazocine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.00171	0.00221	CcSEcCtD
Pentazocine—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.0017	0.0022	CcSEcCtD
Pentazocine—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.0017	0.0022	CcSEcCtD
Pentazocine—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.00169	0.00219	CcSEcCtD
Pentazocine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00169	0.00218	CcSEcCtD
Pentazocine—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.00169	0.0092	CbGpPWpGaD
Pentazocine—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.00168	0.00217	CcSEcCtD
Pentazocine—EBP—Metabolism—TAT—acquired immunodeficiency syndrome	0.00167	0.00913	CbGpPWpGaD
Pentazocine—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.00167	0.00216	CcSEcCtD
Pentazocine—Shock—Efavirenz—acquired immunodeficiency syndrome	0.00166	0.00215	CcSEcCtD
Pentazocine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00166	0.00214	CcSEcCtD
Pentazocine—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.00165	0.00213	CcSEcCtD
Pentazocine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.00165	0.00213	CcSEcCtD
Pentazocine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00165	0.00213	CcSEcCtD
Pentazocine—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.00165	0.00213	CcSEcCtD
Pentazocine—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.00165	0.00212	CcSEcCtD
Pentazocine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.00164	0.00212	CcSEcCtD
Pentazocine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.00164	0.00212	CcSEcCtD
Pentazocine—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.00164	0.00212	CcSEcCtD
Pentazocine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00163	0.00211	CcSEcCtD
Pentazocine—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.00163	0.00211	CcSEcCtD
Pentazocine—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.00163	0.0021	CcSEcCtD
Pentazocine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00163	0.0021	CcSEcCtD
Pentazocine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00162	0.00209	CcSEcCtD
Pentazocine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00162	0.00209	CcSEcCtD
Pentazocine—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.00162	0.00209	CcSEcCtD
Pentazocine—SIGMAR1—lung—acquired immunodeficiency syndrome	0.00162	0.038	CbGeAlD
Pentazocine—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.00162	0.00209	CcSEcCtD
Pentazocine—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.00162	0.00209	CcSEcCtD
Pentazocine—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.00161	0.00208	CcSEcCtD
Pentazocine—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.00161	0.00208	CcSEcCtD
Pentazocine—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00161	0.00879	CbGpPWpGaD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00161	0.00878	CbGpPWpGaD
Pentazocine—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00161	0.00877	CbGpPWpGaD
Pentazocine—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.00161	0.00207	CcSEcCtD
Pentazocine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00161	0.00207	CcSEcCtD
Pentazocine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.0016	0.00207	CcSEcCtD
Pentazocine—Headache—Didanosine—acquired immunodeficiency syndrome	0.0016	0.00206	CcSEcCtD
Pentazocine—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00159	0.00206	CcSEcCtD
Pentazocine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00159	0.00206	CcSEcCtD
Pentazocine—Shock—Delavirdine—acquired immunodeficiency syndrome	0.00159	0.00205	CcSEcCtD
Pentazocine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00159	0.00205	CcSEcCtD
Pentazocine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00159	0.00205	CcSEcCtD
Pentazocine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00158	0.00205	CcSEcCtD
Pentazocine—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.00158	0.00205	CcSEcCtD
Pentazocine—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00158	0.00204	CcSEcCtD
Pentazocine—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.00158	0.00204	CcSEcCtD
Pentazocine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.00158	0.00204	CcSEcCtD
Pentazocine—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.00158	0.00203	CcSEcCtD
Pentazocine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00157	0.00203	CcSEcCtD
Pentazocine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00157	0.00202	CcSEcCtD
Pentazocine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00156	0.00202	CcSEcCtD
Pentazocine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00156	0.00202	CcSEcCtD
Pentazocine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00156	0.00202	CcSEcCtD
Pentazocine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.00155	0.00201	CcSEcCtD
Pentazocine—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.00155	0.002	CcSEcCtD
Pentazocine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00154	0.00199	CcSEcCtD
Pentazocine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.00154	0.00199	CcSEcCtD
Pentazocine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00153	0.00197	CcSEcCtD
Pentazocine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00153	0.00197	CcSEcCtD
Pentazocine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00152	0.00197	CcSEcCtD
Pentazocine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.00152	0.00197	CcSEcCtD
Pentazocine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00152	0.00196	CcSEcCtD
Pentazocine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00152	0.00196	CcSEcCtD
Pentazocine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00151	0.00195	CcSEcCtD
Pentazocine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00151	0.00195	CcSEcCtD
Pentazocine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.00151	0.00195	CcSEcCtD
Pentazocine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00151	0.00195	CcSEcCtD
Pentazocine—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.00151	0.00195	CcSEcCtD
Pentazocine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00151	0.00195	CcSEcCtD
Pentazocine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00151	0.00195	CcSEcCtD
Pentazocine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.0015	0.00194	CcSEcCtD
Pentazocine—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0015	0.00818	CbGpPWpGaD
Pentazocine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00149	0.00193	CcSEcCtD
Pentazocine—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00148	0.00809	CbGpPWpGaD
Pentazocine—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.00148	0.00191	CcSEcCtD
Pentazocine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00147	0.0019	CcSEcCtD
Pentazocine—Shock—Ritonavir—acquired immunodeficiency syndrome	0.00147	0.0019	CcSEcCtD
Pentazocine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.00147	0.0019	CcSEcCtD
Pentazocine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00147	0.0019	CcSEcCtD
Pentazocine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00147	0.00189	CcSEcCtD
Pentazocine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00146	0.00189	CcSEcCtD
Pentazocine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00146	0.00189	CcSEcCtD
Pentazocine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00146	0.00188	CcSEcCtD
Pentazocine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00146	0.00188	CcSEcCtD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00145	0.00794	CbGpPWpGaD
Pentazocine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00145	0.00187	CcSEcCtD
Pentazocine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.00145	0.00187	CcSEcCtD
Pentazocine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.00144	0.00187	CcSEcCtD
Pentazocine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00144	0.00187	CcSEcCtD
Pentazocine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00144	0.00186	CcSEcCtD
Pentazocine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.00144	0.00186	CcSEcCtD
Pentazocine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00144	0.00186	CcSEcCtD
Pentazocine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00144	0.00186	CcSEcCtD
Pentazocine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00144	0.00185	CcSEcCtD
Pentazocine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.00142	0.00184	CcSEcCtD
Pentazocine—EBP—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00142	0.00777	CbGpPWpGaD
Pentazocine—Shock—Saquinavir—acquired immunodeficiency syndrome	0.00142	0.00183	CcSEcCtD
Pentazocine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00141	0.00182	CcSEcCtD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00141	0.0077	CbGpPWpGaD
Pentazocine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00141	0.00182	CcSEcCtD
Pentazocine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.0014	0.00181	CcSEcCtD
Pentazocine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.0014	0.00181	CcSEcCtD
Pentazocine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.0014	0.0018	CcSEcCtD
Pentazocine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.0014	0.0018	CcSEcCtD
Pentazocine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00139	0.0018	CcSEcCtD
Pentazocine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00139	0.0018	CcSEcCtD
Pentazocine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.00139	0.0018	CcSEcCtD
Pentazocine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00139	0.0018	CcSEcCtD
Pentazocine—OPRM1—brain—acquired immunodeficiency syndrome	0.00139	0.0326	CbGeAlD
Pentazocine—Headache—Stavudine—acquired immunodeficiency syndrome	0.00139	0.00179	CcSEcCtD
Pentazocine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00139	0.00179	CcSEcCtD
Pentazocine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.00138	0.00179	CcSEcCtD
Pentazocine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00138	0.00179	CcSEcCtD
Pentazocine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00138	0.00178	CcSEcCtD
Pentazocine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00137	0.00177	CcSEcCtD
Pentazocine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.00137	0.00177	CcSEcCtD
Pentazocine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.00137	0.00177	CcSEcCtD
Pentazocine—Headache—Abacavir—acquired immunodeficiency syndrome	0.00136	0.00176	CcSEcCtD
Pentazocine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00136	0.00176	CcSEcCtD
Pentazocine—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00136	0.00743	CbGpPWpGaD
Pentazocine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00136	0.00176	CcSEcCtD
Pentazocine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00135	0.00175	CcSEcCtD
Pentazocine—Shock—Lamivudine—acquired immunodeficiency syndrome	0.00135	0.00174	CcSEcCtD
Pentazocine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.00134	0.00174	CcSEcCtD
Pentazocine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00134	0.00173	CcSEcCtD
Pentazocine—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00134	0.00731	CbGpPWpGaD
Pentazocine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00133	0.00172	CcSEcCtD
Pentazocine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00133	0.00172	CcSEcCtD
Pentazocine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.00133	0.00172	CcSEcCtD
Pentazocine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00133	0.00171	CcSEcCtD
Pentazocine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00132	0.0017	CcSEcCtD
Pentazocine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.00132	0.0017	CcSEcCtD
Pentazocine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.00132	0.0017	CcSEcCtD
Pentazocine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00131	0.0017	CcSEcCtD
Pentazocine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.00131	0.00169	CcSEcCtD
Pentazocine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.0013	0.00168	CcSEcCtD
Pentazocine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.0013	0.00168	CcSEcCtD
Pentazocine—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.0013	0.00709	CbGpPWpGaD
Pentazocine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00129	0.00167	CcSEcCtD
Pentazocine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00129	0.00167	CcSEcCtD
Pentazocine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00128	0.00166	CcSEcCtD
Pentazocine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00128	0.00166	CcSEcCtD
Pentazocine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.00128	0.00166	CcSEcCtD
Pentazocine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00128	0.00165	CcSEcCtD
Pentazocine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00128	0.00165	CcSEcCtD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00128	0.00696	CbGpPWpGaD
Pentazocine—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.00127	0.00694	CbGpPWpGaD
Pentazocine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00127	0.00164	CcSEcCtD
Pentazocine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00126	0.00163	CcSEcCtD
Pentazocine—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00126	0.00688	CbGpPWpGaD
Pentazocine—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00126	0.00688	CbGpPWpGaD
Pentazocine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.00125	0.00162	CcSEcCtD
Pentazocine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00124	0.00161	CcSEcCtD
Pentazocine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.00124	0.0016	CcSEcCtD
Pentazocine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.00123	0.00159	CcSEcCtD
Pentazocine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00123	0.00159	CcSEcCtD
Pentazocine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00123	0.00159	CcSEcCtD
Pentazocine—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00122	0.00669	CbGpPWpGaD
Pentazocine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.00122	0.00158	CcSEcCtD
Pentazocine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00122	0.00158	CcSEcCtD
Pentazocine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00122	0.00158	CcSEcCtD
Pentazocine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00122	0.00158	CcSEcCtD
Pentazocine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00121	0.00157	CcSEcCtD
Pentazocine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00121	0.00156	CcSEcCtD
Pentazocine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.0012	0.00156	CcSEcCtD
Pentazocine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.0012	0.00154	CcSEcCtD
Pentazocine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.00119	0.00154	CcSEcCtD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00119	0.00651	CbGpPWpGaD
Pentazocine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00119	0.00154	CcSEcCtD
Pentazocine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00119	0.00153	CcSEcCtD
Pentazocine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00118	0.00153	CcSEcCtD
Pentazocine—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00117	0.00641	CbGpPWpGaD
Pentazocine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00117	0.00152	CcSEcCtD
Pentazocine—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.00116	0.00635	CbGpPWpGaD
Pentazocine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00116	0.0015	CcSEcCtD
Pentazocine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.00116	0.00149	CcSEcCtD
Pentazocine—SIGMAR1—brain—acquired immunodeficiency syndrome	0.00115	0.0269	CbGeAlD
Pentazocine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00114	0.00148	CcSEcCtD
Pentazocine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00114	0.00147	CcSEcCtD
Pentazocine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00114	0.00147	CcSEcCtD
Pentazocine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.00113	0.00146	CcSEcCtD
Pentazocine—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00113	0.00617	CbGpPWpGaD
Pentazocine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00113	0.00145	CcSEcCtD
Pentazocine—Headache—Indinavir—acquired immunodeficiency syndrome	0.00112	0.00145	CcSEcCtD
Pentazocine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00112	0.00144	CcSEcCtD
Pentazocine—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00111	0.00605	CbGpPWpGaD
Pentazocine—SIGMAR1—lymph node—acquired immunodeficiency syndrome	0.00111	0.026	CbGeAlD
Pentazocine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.00111	0.00143	CcSEcCtD
Pentazocine—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.0011	0.00603	CbGpPWpGaD
Pentazocine—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.0011	0.00603	CbGpPWpGaD
Pentazocine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.0011	0.00142	CcSEcCtD
Pentazocine—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.0011	0.00599	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00108	0.00588	CbGpPWpGaD
Pentazocine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00107	0.00139	CcSEcCtD
Pentazocine—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00107	0.00586	CbGpPWpGaD
Pentazocine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.00107	0.00138	CcSEcCtD
Pentazocine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00107	0.00138	CcSEcCtD
Pentazocine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.00106	0.00137	CcSEcCtD
Pentazocine—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00106	0.0058	CbGpPWpGaD
Pentazocine—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00106	0.0058	CbGpPWpGaD
Pentazocine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00106	0.00137	CcSEcCtD
Pentazocine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00106	0.00137	CcSEcCtD
Pentazocine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00106	0.00137	CcSEcCtD
Pentazocine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00106	0.00137	CcSEcCtD
Pentazocine—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00105	0.00573	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00104	0.00566	CbGpPWpGaD
Pentazocine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.00103	0.00133	CcSEcCtD
Pentazocine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00103	0.00133	CcSEcCtD
Pentazocine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00102	0.00132	CcSEcCtD
Pentazocine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00102	0.00131	CcSEcCtD
Pentazocine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00102	0.00131	CcSEcCtD
Pentazocine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00101	0.00131	CcSEcCtD
Pentazocine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00101	0.00131	CcSEcCtD
Pentazocine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.001	0.0013	CcSEcCtD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000993	0.00542	CbGpPWpGaD
Pentazocine—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000993	0.00542	CbGpPWpGaD
Pentazocine—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000991	0.00541	CbGpPWpGaD
Pentazocine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000988	0.00128	CcSEcCtD
Pentazocine—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000986	0.00538	CbGpPWpGaD
Pentazocine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000985	0.00127	CcSEcCtD
Pentazocine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000984	0.00127	CcSEcCtD
Pentazocine—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000971	0.0053	CbGpPWpGaD
Pentazocine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000971	0.00125	CcSEcCtD
Pentazocine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00096	0.00124	CcSEcCtD
Pentazocine—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000958	0.00523	CbGpPWpGaD
Pentazocine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000951	0.00123	CcSEcCtD
Pentazocine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00095	0.00123	CcSEcCtD
Pentazocine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000941	0.00122	CcSEcCtD
Pentazocine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000939	0.00121	CcSEcCtD
Pentazocine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000936	0.00121	CcSEcCtD
Pentazocine—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000933	0.0051	CbGpPWpGaD
Pentazocine—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000933	0.0051	CbGpPWpGaD
Pentazocine—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000932	0.00509	CbGpPWpGaD
Pentazocine—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000932	0.00509	CbGpPWpGaD
Pentazocine—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00092	0.00502	CbGpPWpGaD
Pentazocine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000915	0.00118	CcSEcCtD
Pentazocine—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000909	0.00497	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000907	0.00495	CbGpPWpGaD
Pentazocine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000907	0.00117	CcSEcCtD
Pentazocine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000906	0.00117	CcSEcCtD
Pentazocine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000901	0.00116	CcSEcCtD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000898	0.00491	CbGpPWpGaD
Pentazocine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000888	0.00115	CcSEcCtD
Pentazocine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000873	0.00113	CcSEcCtD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000871	0.00476	CbGpPWpGaD
Pentazocine—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000865	0.00472	CbGpPWpGaD
Pentazocine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000864	0.00112	CcSEcCtD
Pentazocine—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000863	0.00471	CbGpPWpGaD
Pentazocine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00086	0.00111	CcSEcCtD
Pentazocine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000854	0.0011	CcSEcCtD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000845	0.00461	CbGpPWpGaD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000845	0.00461	CbGpPWpGaD
Pentazocine—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00084	0.00459	CbGpPWpGaD
Pentazocine—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000837	0.00457	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000821	0.00448	CbGpPWpGaD
Pentazocine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000815	0.00105	CcSEcCtD
Pentazocine—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000808	0.00441	CbGpPWpGaD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000788	0.0043	CbGpPWpGaD
Pentazocine—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000787	0.0043	CbGpPWpGaD
Pentazocine—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000787	0.0043	CbGpPWpGaD
Pentazocine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000777	0.00424	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000769	0.0042	CbGpPWpGaD
Pentazocine—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000757	0.00413	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000757	0.00413	CbGpPWpGaD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000741	0.00404	CbGpPWpGaD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000741	0.00404	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000736	0.00402	CbGpPWpGaD
Pentazocine—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000731	0.00399	CbGpPWpGaD
Pentazocine—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.00073	0.00399	CbGpPWpGaD
Pentazocine—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000728	0.00398	CbGpPWpGaD
Pentazocine—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00071	0.00388	CbGpPWpGaD
Pentazocine—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000709	0.00387	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000684	0.00374	CbGpPWpGaD
Pentazocine—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000676	0.00369	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000666	0.00364	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000663	0.00362	CbGpPWpGaD
Pentazocine—EBP—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	0.000655	0.00358	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000643	0.00351	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000643	0.00351	CbGpPWpGaD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000643	0.00351	CbGpPWpGaD
Pentazocine—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00064	0.00349	CbGpPWpGaD
Pentazocine—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000638	0.00349	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000628	0.00343	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000626	0.00342	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000626	0.00342	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000613	0.00335	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.0006	0.00328	CbGpPWpGaD
Pentazocine—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000599	0.00327	CbGpPWpGaD
Pentazocine—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000593	0.00324	CbGpPWpGaD
Pentazocine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000579	0.00316	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000568	0.0031	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000564	0.00308	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000564	0.00308	CbGpPWpGaD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000563	0.00308	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000561	0.00306	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000551	0.00301	CbGpPWpGaD
Pentazocine—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00054	0.00295	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000537	0.00293	CbGpPWpGaD
Pentazocine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000508	0.00277	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000507	0.00277	CbGpPWpGaD
Pentazocine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000501	0.00273	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000498	0.00272	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000489	0.00267	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000477	0.0026	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000477	0.0026	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000476	0.0026	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000466	0.00254	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000454	0.00248	CbGpPWpGaD
Pentazocine—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000441	0.00241	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000429	0.00234	CbGpPWpGaD
Pentazocine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000429	0.00234	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000421	0.0023	CbGpPWpGaD
Pentazocine—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000395	0.00216	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000388	0.00212	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000387	0.00211	CbGpPWpGaD
Pentazocine—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000387	0.00211	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000371	0.00203	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000371	0.00203	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000364	0.00198	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000364	0.00198	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000363	0.00198	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000351	0.00192	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00034	0.00186	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000339	0.00185	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000336	0.00183	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00033	0.0018	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00033	0.0018	CbGpPWpGaD
Pentazocine—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000327	0.00178	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000326	0.00178	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000326	0.00178	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000319	0.00174	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000319	0.00174	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000308	0.00168	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000294	0.00161	CbGpPWpGaD
Pentazocine—EBP—Metabolism—ALB—acquired immunodeficiency syndrome	0.000292	0.00159	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000289	0.00158	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000289	0.00158	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000288	0.00157	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000287	0.00156	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000277	0.00151	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000275	0.0015	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000275	0.0015	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000272	0.00149	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000269	0.00147	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000269	0.00147	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00026	0.00142	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000251	0.00137	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000249	0.00136	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000249	0.00136	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000247	0.00135	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000245	0.00134	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000245	0.00134	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000242	0.00132	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000239	0.0013	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000229	0.00125	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000226	0.00124	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00022	0.0012	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000218	0.00119	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000217	0.00118	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000207	0.00113	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000205	0.00112	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000202	0.0011	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000201	0.0011	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000198	0.00108	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000195	0.00106	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000195	0.00106	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000186	0.00102	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000185	0.00101	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000183	0.001	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000182	0.000993	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000171	0.000934	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000171	0.000934	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00017	0.000928	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000168	0.000915	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000154	0.000839	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000148	0.00081	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000146	0.000798	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000145	0.000789	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000145	0.000789	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000144	0.000786	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000134	0.00073	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000131	0.000714	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.00013	0.00071	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000128	0.0007	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000126	0.000689	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000117	0.00064	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000115	0.000626	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.00011	0.0006	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000108	0.000591	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000107	0.000582	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.9e-05	0.000541	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.69e-05	0.000529	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.72e-05	0.000422	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.68e-05	0.00042	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.77e-05	0.00037	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.74e-05	0.000368	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.72e-05	0.000312	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.69e-05	0.000311	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.54e-05	0.000248	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.98e-05	0.000217	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.36e-05	0.000184	CbGpPWpGaD
